Return to search results.
Complete title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
|Research Study Number||20111531|
|Principal Investigator||Maciej Mrugala, MD, PhD|
Research Study Description
All patients will be administered temozolomide, the standard treatment for glioblastoma. Half the patients will be randomly assigned to receive rindopepimut and half the patients will be randomly assigned to receive a control called keyhole limpet hemocyanin.
Patients will be treated in a blinded fashion (neither the patient or the doctor will know which arm of the study the patient is on). Patients will be treated until disease progression or intolerance to therapy and all patients will be followed for survival.
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Astrocytomas; Brain Cancer; Glioblastoma Multiforme; Glioma; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.